诺诚健华2024年减亏至4.4亿 连亏7年2022年上市募29亿

Group 1: Financial Performance - The company expects revenue from Oubatinib to reach approximately RMB 1,001 million in 2024, representing a growth of about 49% compared to the previous year [1] - The total operating revenue is projected to be around RMB 1,010 million, reflecting a growth of approximately 37% year-on-year [1] - The net profit attributable to the parent company is expected to be around RMB -443 million, indicating a reduction in losses by about 30% compared to the previous year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be around RMB -444 million, showing a decrease in losses of approximately 29% year-on-year [1] - In 2023, the company reported an operating revenue of RMB 739 million, a year-on-year increase of 18.09% [1] - The net profit attributable to shareholders was RMB -631 million in 2023, compared to RMB -887 million in 2022 [1] - The net profit after deducting non-recurring gains and losses was RMB -626 million in 2023, compared to RMB -960 million in 2022 [1] - The net cash flow from operating activities was RMB -665 million in 2023, compared to RMB -491 million in 2022 [1] - The company has reported losses for six consecutive years [1] Group 2: IPO and Fundraising - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 21, 2022, with an initial public offering of 264,648,217 shares at a price of RMB 11.03 per share [2] - The total amount raised from the initial public offering was RMB 2,919.07 million, with a net amount of RMB 2,778.82 million after expenses [3] - The actual net fundraising amount was RMB 122.12 million less than the originally planned amount of RMB 4,000 million [4] - The funds were intended for new drug research and development, upgrading drug research platforms, building marketing networks, information technology construction, and supplementing working capital [4] - The total issuance costs for the initial public offering amounted to RMB 140.25 million, with underwriting and sponsorship fees accounting for RMB 112.17 million [5]